Immunoassay for Neurological Biomarkers - Global Strategic Business Report

The global market for Immunoassay for Neurological Biomarkers was estimated at US$809.9 Million in 2024 and is projected to reach US$2.1 Billion by 2030, growing at a CAGR of 17.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Immunoassay for Neurological Biomarkers market.

Global Immunoassay for Neurological Biomarkers Market - Advancing Neurodiagnostics

Why Are Immunoassays Becoming Crucial in Neurology?

Immunoassays for neurological biomarkers are gaining significant traction due to their ability to detect and quantify proteins associated with neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. The rising prevalence of these conditions, coupled with an aging population, has driven demand for early and accurate diagnostic tools. Immunoassays provide a non-invasive method for detecting neurological biomarkers in blood and cerebrospinal fluid, enabling timely intervention and disease management.

How Are Innovations in Immunoassay Technology Impacting the Market?

Technological advancements, including highly sensitive multiplex immunoassays and digital immunoassays, have improved the precision and scalability of neurological diagnostics. AI-driven data analysis is further refining biomarker detection, allowing for early-stage identification of neurological disorders. Moreover, the development of point-of-care immunoassay platforms is making neurodiagnostics more accessible, reducing dependency on specialized laboratory infrastructure. Portable and home-based diagnostic kits are also emerging, catering to patients who require regular monitoring.

What Are the Market Growth Factors?

The growing focus on early diagnosis of neurodegenerative diseases, increasing investment in biomarker research, and rising collaborations between pharmaceutical and diagnostic companies are major growth drivers in this market. Government initiatives promoting neurological research and advancements in personalized medicine are also contributing to the rapid expansion of immunoassay applications for neurological biomarker detection. Additionally, the pharmaceutical industry is leveraging immunoassays for drug development and clinical trials, further expanding their application.

What Lies Ahead for the Market?

Despite the promising growth, challenges such as regulatory hurdles, cost barriers, and standardization of biomarker panels need to be addressed. However, the increasing integration of AI, automation, and next-generation sequencing is expected to bridge these gaps. As demand for precision medicine grows, immunoassays for neurological biomarkers will play a pivotal role in transforming neurodiagnostics and patient care.

Report Scope

The report analyzes the Immunoassay for Neurological Biomarkers market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Product (Instruments Immunoassay for Neurological Biomarkers, Reagents Immunoassay for Neurological Biomarkers, Services Immunoassay for Neurological Biomarkers); Disease (Alzheimer`s Disease, Parkinson`s Disease, Multiple Sclerosis Disease, Other Diseases); Application (In Vitro Diagnostics Application, Research Application)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Instruments Immunoassay for Neurological Biomarkers segment, which is expected to reach US$1.3 Billion by 2030 with a CAGR of a 19.4%. The Reagents Immunoassay for Neurological Biomarkers segment is also set to grow at 14.2% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $220.6 Million in 2024, and China, forecasted to grow at an impressive 23.2% CAGR to reach $474.9 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Immunoassay for Neurological Biomarkers Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Immunoassay for Neurological Biomarkers Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Immunoassay for Neurological Biomarkers Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, ADx NeuroSciences NV, Banyan Biomarkers, Inc., bioMérieux SA, Bio-Rad Laboratories, Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 47 Featured):

• Abbott Laboratories
• ADx NeuroSciences NV
• Banyan Biomarkers, Inc.
• bioMérieux SA
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• C2N Diagnostics
• EnCor Biotechnology Inc.
• F. Hoffmann-La Roche Ltd
• Fujirebio
• Johnson & Johnson Services, Inc.
• Merck KGaA
• Nimble Therapeutics
• PerkinElmer, Inc.
• QIAGEN N.V.
• Quanterix Corporation
• Quibim
• Siemens Healthineers AG
• Sysmex Corporation
• Thermo Fisher Scientific Inc.

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry